Polyoxidonium pills 12mg №10

Mechanism of action

Azoxymere bromide has a complex effect: immunomodulatory, detoxifying, antioxidant, mild anti-inflammatory.

The basis of the mechanism of immunomodulating action of azoxymere bromide is a direct effect on phagocytic cells and natural killers, as well as stimulation of antibody production and synthesis of Interferon alpha and interferon gamma.

Detoxification and antioxidant properties of azoxymere bromide are largely determined by the structure and high molecular nature of the drug.

Azoximera bromide increases the body's resistance to local and generalized infections of bacterial, fungal and viral etiology. Restores immunity in secondary immunodeficiency states caused by various infections, injuries, complications after surgery.

A characteristic feature of azoxymere bromide in local (sublingual) use is the ability to activate the body's early defense factors against infection: the drug stimulates the bactericidal properties of neutrophils and macrophages, enhances their ability to absorb bacteria, increases the bactericidal properties of saliva and secretions of the mucous membrane of the upper respiratory tract.

When orally administered azoxymere, bromide also activates lymphoid cells in the intestinal lymph nodes.

Azoxymer bromide blocks soluble toxic substances and microparticles, has the ability to excrete toxins, heavy metal salts from the body, inhibits lipid peroxidation, both by intercepting free radicals and by eliminating catalytically active Fe ions²⁺. Azoximera bromide reduces the inflammatory response by normalizing the synthesis of pro- and anti-inflammatory cytokines.

Azoximer bromide is well tolerated, does not possess mitogenic, polyclonal activity, antigenic properties, does not have allergenic, mutagenic, embryotoxic, teratogenic and carcinogenic effects.

Azoxymere bromide is odorless and tasteless; it does not have a local irritant effect when applied to the mucous membranes of the eye, nose, and oropharynx.

Pharmacokinetics

Suction

Azoximer bromide after oral administration is rapidly absorbed from the gastrointestinal tract, the bioavailability of the drug when administered orally is more than 70%. C_maxin blood plasma is achieved 3 hours after ingestion. The pharmacokinetics of azoxymere bromide is linear (plasma concentration is proportional to the dose taken).

Distribution

Azoxymere bromide is a hydrophilic compound. Seeming v_dis about 0.5 l / kg, which suggests that the drug is distributed mainly in the intercellular fluid. The period of semi-absorption is 35 minutes.Azoxymere bromide is rapidly distributed to all organs and tissues of the body, penetrates through the BBB. No cumulative effect.

Metabolism and excretion

In the body, azoxymere bromide is biodegraded to low molecular weight oligomers, which are mainly excreted by the kidneys, with feces not more than 3%. T_1/2 - 18 h.

Indications

Treatment and prevention of acute and chronic respiratory diseases in the acute stage and remission in adults and children from 3 years.

In the complex therapy:

- acute and exacerbations of chronic recurrent infectious and inflammatory diseases of the oropharynx, paranasal sinuses, upper and lower respiratory tract, the inner and middle ear;

- allergic diseases complicated by recurrent bacterial, fungal and viral infections (including pollinosis, bronchial asthma).

In the form of monotherapy:

- prevention of recurrent herpetic nasal and labial infections;

- prevention of exacerbations of chronic foci of infections of the oropharynx, paranasal sinuses, upper respiratory tract, the inner and middle ear;

- prevention of secondary immunodeficiencies arising from aging or exposure to adverse factors.

Dosage and administration

The drug is used orally and sublingually for 20-30 minutes before meals daily 2 times / day.

Adults and children over 10 years appoint 1 tab.,children aged 3 to 10 years - 1/2 tab. (6 mg).

If necessary, it is possible to conduct repeated courses of therapy in 3-4 months.When you reappoint the drug its effectiveness is not reduced.

Sublingual

Fortreatment of influenza and acute respiratory infections adults and children over 10 years appoint 1 tab. 2 times / day 7 days;children aged 3 to 10 years - 1/2 tab. 2 times / day 7 days.

Atinflammatory diseases of the oral cavity and pharynx for adultsappoint 1 tab. 2 times / day for 10 days;children over 10 years old - 1 tab. 2 times / day for 7 days;children aged 3 to 10 years - 1/2 tab. 2 times / day for 7 days.

Atexacerbation of chronic diseases of the upper respiratory tract, paranasal sinuses, chronic otitis for adults appoint 1 pill 2 times / day for 10 days;children over 10 years old - 1 tab. 2 times / day for 7 days.

Fortreatment of allergic diseases (including pollinosis, bronchial asthma), complicated by recurrent bacterial, fungal and viral infectionsfor adults appoint 1 tab. 2 times / day for 10 days;children over 10 years old - 1 tab. 2 times / day for 7 days;children aged 3 to 10 years - 1/2 tab. 2 times / day for 7 days.

Forprevention of influenza and acute respiratory infections in the pre-epidemic period for adults appoint 1 tab. / day for 10 days;children over 10 years old - 1 tab. / day per day for 7 days;children aged 3 to 10 years - 1/2 tab. / day for 7 days.

Forprevention of recurrent herpetic nasal and labial infections for adults appoint 1 tab. 2 times / day 10 days;children over 10 years old - 1 tab. 2 times / day 7 days;children aged 3 to 10 years - 1/2 tab.2 times / day 7 days.

Forprevention of exacerbations of chronic foci of infections of the oropharynx, paranasal sinuses, upper respiratory tract, inner and middle earadults and children over 10 years appoint 1 tab. 1 time / day 10 days;children aged 3 to 10 years - 1/2 tab. 1 time / day for 10 days.

Forprevention of secondary immunodeficiencies arising from aging or exposure to adverse factors for adults appoint 1 tab. 1 time / day for 10 days.

Orally

Atdiseases of the upper and lower respiratory tract adults and children over 10 years appoint 1 tab. 2 times / day 10 days.

Side effect

No side effects reported.

If the patient has noticed any side effects, he should inform the doctor.

Contraindications

- acute renal failure;

- children's age up to 3 years;

- pregnancy;

- lactation period (breastfeeding);

- rare hereditary lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome;

- increased individual sensitivity to the drug.

Carefully It should appoint a drug for chronic renal failure (use no more than 2 times a week).

Use during pregnancy and lactation

Use of the drug Polyoxidonium is contraindicated.^® pregnant women and women during the breastfeeding period (there is no clinical experience).

ATexperimental studies polyoxidonium drug^® no embryotoxic and teratogenic effects, influence on the development of the fetus.

When a pregnancy occurs or when planning a pregnancy, the patient should consult a doctor.

During the period of breastfeeding before using the drug Polyoxidonium^®the patient must consult a doctor.

Application for violations of kidney function

Use of the drug in acute renal failure is contraindicated.

with caution It should appoint a drug for chronic renal failure (use no more than 2 times a week).

Use in children

The use of the drug is contraindicated in children under 3 years.

special instructions

With the development of an allergic reaction, the patient should stop using the drug Polyoxidonium^® and consult a doctor.

If necessary, stop taking the drug Polyoxidonium^® cancellation can be done immediately, without gradually reducing the dose.

In the case of skipping the next dose of the drug, its subsequent use should be carried out as usual, as indicated in the instructions or recommended by the doctor. Do not take a double dose to compensate for missed doses.

Do not use the drug in the presence of visual signs of its unsuitability (defect packaging, discoloration of the tablet).

Influence on ability to drive motor transport and control mechanisms

The use of the drug Polyoxidonium^® does not affect the ability to perform potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions (including driving, working with moving mechanisms).

Overdose

Cases of overdose are not registered.

Drug interaction

Azoximer bromide does not inhibit isoenzymes of CYP1A2, CYP2C9, CYP2C19, CYP2D6, therefore the drug is compatible with antibiotics, antiviral, antifungal and antihistamine drugs, GCS and cytostatics.

If the patient takes the above or other medications (including non-prescription drugs), before starting to take the drug Polyoxidonium^®need to consult a doctor.

Terms and conditions of storage

The drug should be stored out of the reach of children at a temperature of 2 ° to 25 ° C. Do not use after expiration date.

Pharmacy sales terms

The drug is available without a prescription.